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Purpose: Inhibition of phosphoinositide 3 (PI3)-kinase pathway is attractive for cancer 
treatment. To examine the role of the phosphatase and tensin homologue (PTEN) in the 
development of resistance to the treatment.  
Methods: We cultured human prostate cancer cells (DU145 and PC-3 cells), and bladder 
cancer cells (EJ-1 and UM-UC-3 cells) with a PI3-kinase inhibitor, LY294002 for more 
than 6 weeks and cell proliferation was studied. Activation of Akt1 and ERK was 
examined by immunoblotting. We introduced the wild type PTEN in UM-UC-3 cells 
and their prolifartion along with the signaling pathways were also examined. 
Results: After 6-weeks, proliferation pathway sensitivity to LY294002 was reduced in 
cells expressing PTEN, but not in PTEN-null cells. PD98059, a MAPK/ERK kinase 
inhibitor, significantly inhibited proliferation of PTEN-expressing cells, but not 
PTEN-null cells. Stable PTEN expression in PTEN-null UM-UC-3 cells increased 
serum-induced ERK activation and sensitivity to PD98059-treatment, and reduced 
sensitivity to LY294002 after 6-weeks exposure. 
Conclusions: Loss of PTEN function may protect against resistance to PI3-kinase 
inhibitors through an addiction to the PI3-kinase/Akt pathway. 
 
 




Protein serine/threonine kinase Akt plays central roles in the phosphoinositide 3-kinase 
(PI3-kinase)-mediated intracellular signaling. PI3-kinase/Akt pathway is implicated in 
the proliferation, motility, and survival of tumor cells and is important in angiogenesis 
(Jiang et al. 2000; Downward 2004; Bader et al. 2005). The endogenous tumor 
suppressor, phosphatase and tensin homologue (PTEN), dephosphorylates the D3 
position of phosphatidylinositol-3,4,5 triphosphate. This antagonizes 
PI3-kinase-generated second messenger functions and thus inhibits a panel of cellular 
responses mediated by the PI3-kinase/Akt pathway (Ali et al. 1999; Leslie and Downes 
2004; Cully et al. 2006). The loss of functional PTEN is frequently observed in human 
cancers, including prostate and bladder cancers (Cairns et al. 1997; Aveyard et al 1999). 
PTEN deficiency is associated with a number of aggressive tumor cell phenotypes and 
is indicative of a poor prognosis for cancer patients (Ali et al. 1999; Leslie and Downes 
2004; Cully et al. 2006). 
 
A potential strategy for treating advanced and/or recurrent human cancers is the use of 
molecular targeting agents against particular signaling molecules. This strategy may 
directly inhibit the cellular behaviors of tumor cells and may also indirectly inhibit the 
progression of tumors in vivo through the blockade of angiogenesis and tumor-stromal 
interactions. A number of studies have recently shown that cellular loss of functional 
PTEN led to resistance or reduced sensitivity to molecular targeting compounds, 
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irradiation, and chemotherapeutic reagents (Tanaka et al. 2000; Bianco et al. 2003; 
Nagata et al. 2004; Lee et al. 2005; Jiang et al. 2007). This suggests that the presence of 
wild type, functional PTEN may benefit therapeutic efficacy in the treatment of human 
cancers. It has also been shown that loss of functional PTEN increased the sensitivity of 
pathways involving growth inhibition or induction of apoptosis to acute PI3-kinase 
inhibition (Zhang et al. 2003; deGraffenried et al. 2004). Although PI3-kinase inhibitors 
are anticipated to be potent agents in anticancer strategies, the role of PTEN function in 
chronic PI3-kinase inhibition has not been well elucidated. 
 
In the present study, we investigated the effects of long-term exposure of tumor cells to 
a PI3-kinase inhibitor, LY294002, on the proliferation of cultured human prostate and 
bladder cancer cells. We used different cell lines that had different PTEN functionalities 
to examine whether the expression of wild type PTEN would affect the sensitivity of 
tumor cells to this compound. We found that expression of wild type PTEN may reduce 
the sensitivity of pathways involved in proliferation to PI3-kinase inhibition during 
chronic LY294002 exposure. 
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Anti-PTEN polyclonal antibody was purchased from Upstate Cell Signaling Solutions, 
Lake Placid, NY. Anti-vinculin monoclonal antibody (clone hVIN-1), minimal essential 
medium (MEM), non-essential amino acids (NEAA), Ham’s F-12 medium, RPMI-1640 
medium, and hygromycin were obtained from Sigma Chemical Company, St. Louis, 
MO. Anti-phospho-Akt1 rabbit monoclonal antibody (pSer473) and 
anti-phospho-mitogen-activated protein kinase (MAPK) polyclonal antibody 
(pThr202/Tyr204) were purchased from Cell Signaling Technology, Inc., Beverly, MA. 
Small molecular weight kinase inhibitors for PI3-kinase and MAPK/extracellular 
signal-regulated kinase (ERK) kinase (MEK) that directly inhibit their catalytic 
activities, LY294002, and PD98059, were from Merck Co., Tokyo, Japan. Fetal bovine 
serum (FBS) and pcDNA3.1/Hygro plasmid were purchased from Invitrogen, Co. 
Tokyo, Japan. Small, interfering RNA (siRNA) against Human PTEN (HP validated 
PTEN5) and HiPerFect transfection reagent were purchased from Qiagen Japan, Tokyo, 
Japan. Anti-ERK1 polyclonal antibody, anti-Akt1 monoclonal antibody, anti-CK2 
polyclonal antibody (C-18), and CK2 siRNA (a pool of 3 target-specific siRNAs of 20 
– 25 nucleotides) were obtained from Santa Cruz Biotechnologies, Santa Cruz, CA. 






Two human prostate carcinoma cell lines, DU145 and PC-3, obtained from the 
American Type Culture Collection, were cultured in Ham’s F-12 medium supplemented 
with 10% FBS and RPMI-1640 medium supplemented with 10% FBS, respectively. 
Two human bladder carcinoma cell lines, EJ-1 (Japanese Cancer Research Resource 
Bank) and UM-UC-3 (generous gift from Dr. Hiro-omi Kanayama), were cultured in 
MEM supplemented with NEAA and 10% FBS. For chronic exposure, cells were 
cultured in the presence of 10 M LY294002 for more than 6 weeks. We used 10 M 
LY294002, because this concentration consistently caused statistically significant 
inhibition of proliferation. The culture medium was refreshed every other day. As 
described below, cells were examined biologically and biochemically in the presence or 
absence of LY294002 (short-period treatments). To avoid confusion, parental cells 
cultured without LY294002 were denoted (pa) cells, and cells chronically exposed to 
LY294002 were denoted (LY) cells. (LY) cells were cultured with LY294002 in all 
assays, except when otherwise specified. 
 
Cell proliferation assay 
 
Cells were suspended in medium containing 10% FBS and seeded into 24-well plates (1 
104 cells/well) in the presence of 0.1% DMSO, LY294002, or PD98059 at the 
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indicated concentrations. On the next day, the medium was changed with freshly 
prepared medium containing either DMSO or inhibitor compounds. On the third day 
after seeding, cells were detached with trypsin and counted with a hemacytometer. 
 
Examination of labeling index 
 
Labeling indices were examined to determine numbers of cells in S-phase using the 
Bromodeoxyuridine (BrdU) In-Situ detection kit® (BD Biosciences Pharmingen, San 
Diego, CA) as described before (Kanda et al. 2005). In brief, cells with either 0.1% 
DMSO or 10 M LY294002 were seeded into wells of 48-well-culture plates at a 
density of 2 x104cells/cm2. After 2 days, cells were pulse-labeled for 4 h with 10 M of 
BrdU. Cells were then fixed with the fixation buffer provided in the kit, treated with 
70% ethanol for 20 min, and incubated with 4 M HCl for 20 min. Cells were washed 
and incubated with biotinylated anti-BrdU antibody, followed by sequential incubation 
with streptoavidin-horseradish peroxidase and diaminobenzidine. Finally, cells were 
counter-stained with hematoxylin and photographs were taken under a light microscope. 
At least 500 cells were counted for each well, and labeling indices were determined as 
labeled nuclei/total nuclei ratios and expressed as percentages. 
 
Immunoprecipitation and immunoblotting 
 
Immunoprecipitation and immunoblotting were performed as described previously 
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(Kanda et al. 2006b). In brief, cells were incubated in serum-free medium overnight. 
Cells were stimulated with 10% FBS for 10 min; controls remained serum-free. Cells 
were then lysed in Triton X-100 lysis buffer. Akt1 was immunoprecipitated and 
separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE). After transfer onto 
polyvinylidene difluoride membranes, the blots were probed with antibodies, as 
indicated in the Figures. To determine the expression of PTEN and activation of 
MAPK/ERK, after stimulation with 10% FBS as described above, cells were lysed by 
incubation with boiled SDS-sample buffer followed by the separation with SDS-PAGE, 
and immunoblotting. To examine the expression of other proteins, blots were stripped as 
described previously (Kanda et al. 2000), and reprobed with the appropriate antibodies.   
 
Transfection of siRNA 
 
Cells were transfected with siRNA using HiPerFect reagent as described previously 
(Kanda et al. 2006a). Briefly, cells were seeded at 2104 cells/well in 24-well plates and 
cultured overnight. Cells were transfected with the indicated siRNA and cell number 
was counted 3 days later. Downregulation of target proteins was examined by 
immunoblotting by the use of total cell lysate (CK2 and PTEN). To examine the effect 
of downregulation of PTEN on Akt1 phosphorylation, EJ-1 cells were cultured in 6 cm 
dishes, treated with PTEN siRNA, and Akt1 was immunoprecipitated from 95% of total 




Transfection of wild type PTEN 
 
The plasmid containing the wild type PTEN (Al-Khouri et al. 2005) was a kind gift 
from Dr. Anna Maria Al-Khouri. The PTEN plasmid comprised the wild type PTEN 
cDNA subcloned into the pcDNA3.1/Hygro vector. PC-3 cells or UM-UC-3 cells were 
transfected with a mixture of PTEN plasmid and FuGENE 6 reagent. After 48 h, stably 
transfected cells were selected with hygromycin. After 2 weeks, hygromycin-resistant 
clones were picked up and the expression of PTEN was confirmed by immunoblotting. 
We first transfected the PTEN expression plasmid into PC-3 cells with various amounts 
of plasmid DNA and three different kinds of liposomes. However, we could obtain only 
two stable cell lines that expressed a very small amount of wild type PTEN. These cells 
had a doubling time of more than 6 days (data not shown), and therefore were not 
adequate for our study. We then attempted to make stable UM-UC-3 cell lines 
expressing wild type PTEN. Only three hygromycin-resistant clones were obtained after 
several transfections. Among them, one clone was found to express wild type PTEN at 
satisfactory levels for our study. We also established a control cell line that contained 




Values are presented as mean cell numbers ± SD. Differences between two groups were 
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examined by Mann-Whitney’s U test. Differences were considered significant when the 




Chronic treatment with LY294002 effects on the sensitivity of proliferation to this 
compound in human prostate and bladder cancer cells.  
 
We first examined the expression of PTEN in two human hormone refractory prostate 
cancer cell lines, DU145 and PC-3. As shown in Fig. 1 A, DU145 cells expressed PTEN, 
and PC-3 cells did not. We next examined the acute effect of LY294002 on Akt1 
phosphorylation at Ser 473 (and subsequent activation). In DU145 cells, Akt1 was 
phosphorylated by serum treatment and this phosphorylation was blocked by LY294002 
(Fig. 1 B). In PC-3 cells, Akt1 was strongly phosphorylated, even in the absence of 
serum, and LY294002 blocked both basal and serum-induced Akt1 phosphorylation (Fig. 
1 B). To examine the effects of chronic LY294002 treatment, we cultured DU145 and 
PC-3 cells for more than 6 weeks with 10 M LY294002. As shown in Fig. 1 C, serum 
treatment stimulated Akt1 phosphorylation in untreated DU145 (pa) and PC-3 (pa) cells. 
Interestingly, serum also induced the phosphorylation of Akt1 in chronically treated 
DU145 (LY) and PC-3 (LY) cells. This result indicates that after chronic exposure of 
cells to LY294002, Akt1 could be phosphorylated by external stimuli (serum) even in 
the presence of LY294002. 
We then examined the effect of acute LY294002 treatment on the proliferation of these 
cells. As shown in Fig. 2 A, LY294002 dose-dependently inhibited the proliferation of 
DU145 (pa) and PC-3 (pa) cells. The sensitivity of proliferation to LY294002 was 
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reduced after chronic LY294002 treatment in DU145 (LY) cells, but not in PC-3 (LY) 
cells. Labeling index (a percentage of S-phase cells) was also examined. As shown in 
Fig. 2 B, LY294002 at 10 M significantly inhibited the entry of cells into S-phase by 
DU145 (pa), PC-3 (pa), and PC-3 (LY) cells, but not by DU145 (LY) cells. Thus, 
chronic exposure to LY294002 reduced the sensitivity of proliferation to LY294002 in 
DU145 cells. The IC50 value for LY294002-induced inhibition of cell proliferation was 
increased 21.4-fold in DU145 (LY) cells compared to DU145 (pa) cells (Table 1). 
However, the IC50 was similar in PC-3 (LY) and PC-3 (pa) cells.  
 
We also examined the effect of chronic LY294002 exposure on proliferation of bladder 
cancer cells. Untreated EJ-1 cells expressed PTEN protein, but UM-UC-3 cells did not 
(Fig. 3 A). To examine whether PTEN expressed in EJ-1 is functionally active, we 
downregulated the expression of endogenous PTEN by siRNA and examined Akt1 
phosphorylation. PTEN siRNA efficiently downregulated the endogenous PTEN in EJ-1 
cells. As expected, PTEN siRNA treatment increased basal Akt1 phosphorylation in 
EJ-1 cells (data not shown), suggesting that PTEN in EJ-1 cells was functionally active. 
We examined the effect of acute LY294002 treatments on serum-induced 
phosphorylation of Akt1 in bladder cancer cells. As shown in Fig. 3 B, serum induced 
the phosphorylation of Akt1 in EJ-1 cells. In UM-UC-3 cells, Akt1 was phosphorylated 
even in the absence of serum. In both EJ-1 and UM-UC-3 cells, Akt1 phosphorylation 
was potently inhibited by LY294002 treatments. Next, we examined the effect of 
chronic LY294002 treatments. After the cultivation of these cells for six weeks in the 
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presence or absence of 10 M LY294002, serum-induced phosphorylation of Akt-1 was 
examined. As shown in Fig. 3 C, in both EJ-1 (LY) and UM-UC-3 (LY) cells, serum 
was able to induce the phosphorylation of Akt-1 in the presence of LY294002. We also 
studied the effect of LY294002 on the proliferation of these cells and obtained IC50 
values (Table 1). EJ-1 (LY) cells were 13.8-fold more resistant to LY294002-mediated 
growth inhibition than untreated EJ-1 parental (pa) cells. However, there was no 
significant difference observed in UM-UC-3 (LY) and (pa) cells.  
Because LY294002 can also inhibit the protein kinase, CK2 (Stein 2001), we 
hypothesized that in DU145 (LY) and EJ-1 (LY) cells, CK2 (the catalytic subunit of 
CK2) may participate in the reduced sensitivity of proliferation to LY294002. To 
investigate this hypothesis, we downregulated the expression of CK2 by siRNA in 
DU145 (pa), DU145 (LY), EJ-1 (pa), and EJ-1 (LY) cells, and examined proliferation in 
the presence or absence of LY294002. As shown in Fig. 4 A, treatment of cells with 
siRNA for CK2 efficiently downregulated its expression. In the absence of LY294002, 
downregulation of CK2 mildly (but insignificantly) inhibited the proliferation of EJ-1 
cells, but not of DU145 cells (Fig. 4 B). However, in the presence of LY294002, 
downregulation of CK2did not inhibit the proliferation of either DU145 (LY) or EJ-1 
(LY) cells.  
 
The MEK inhibitor, PD98059, is more effective on proliferation of tumor cells with 
PTEN than those without PTEN 
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Oncogene addiction is a specific dependence of cancer cell proliferation on a particular 
signaling pathway (Weinstein 2002; Lim and Counter 2005) Since PC-3 and UM-UC-3 
cells did not develop resistance to LY294002 after long-term exposure, proliferation of 
these cells may be more dependent on the PI3-kinase pathways than on other signaling 
pathways, such as the ERK/MAPK pathway. To explore a possible PI3-kinase addiction, 
we treated the cells with an ERK/MAPK kinase (MEK) inhibitor, PD98059, and 
investigated activation of ERK and cell proliferation. As shown in Fig. 5 A, serum was 
able to activate ERK by phosphorylation (phosphoMAPK) in all prostate and bladder 
cancer cells. However, the extent of ERK activation in PC-3 cells and UM-UC-3 cells 
was less than that in DU145 or EJ-1 cells. PD98059 potently inhibited serum-induced 
ERK activation in all cells. We next examined the proliferation of these cells in the 
presence of PD98059. As shown in Fig. 5 B, PD98059 significantly inhibited the 
proliferation of DU145 and EJ-1 cells, but not PC-3 and UM-UC-3 cells. The results 
suggest that the loss of functional PTEN protein appears to reduce the sensitivity of 
cellular proliferation to PD98059 and thus, it may cause addiction to the PI3-kinase 
pathway. 
 
Expression of wild type PTEN in UM-UC-3 cells reduces sensitivity of proliferation to 
chronic LY294002 exposure  
 
We next examined the effect of wild type PTEN expression in the resistance of 
proliferation to LY294002. Because an inducible expression system potentially causes 
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growth arrest upon PTEN expression, we established a stable cell line by expressing 
wild type PTEN in PTEN-null cells. Stable expression of wild type PTEN was 
maintained in a UM-UC-3 cell line and was denoted PTEN-8 (Fig. 6 A). We next 
examined the serum-induced activation of ERK and Akt. As shown in Fig. 6 B, 
serum-induced ERK activation was stronger in PTEN-8 cells than in mock transfected 
cells (Mock). Conversely, phosphorylation of both basal and serum-activated Akt1 in 
PTEN-8 cells was lower than that in Mock cells (Fig. 6 C). We also examined the 
effects of PD98059 and LY294002 on proliferation. As shown in Fig. 6 D, PD98059 
more potently inhibited the proliferation of PTEN-8 cells than that of Mock cells. 
However, LY294002 inhibited proliferation similarly in Mock and PTEN-8 cells. When 
LY294002 and PD98059 was added simultaneously, inhibition of proliferation by 
LY294002 was further enhanced by PD98059-treatment in PTEN-8 cells, but not in 
Mock cells. We assessed the IC50 values of parental, Mock, and PTEN-8 cells after 6 
weeks in the presence or absence of 10 M LY294002. As shown in Table 2, expression 
of wild type PTEN in UM-UC-3 cells significantly reduced the sensitivity of 




Synthetic, small molecular weight PI3-kinase inhibitors could be a potentially effective 
therapeutic strategy for recurrent and advanced human cancers. However, the efficacy 
of many anti-tumor approaches, including molecular targeting and chemotherapy, is 
frequently reduced by the loss or mutation of PTEN in human cancers (Tanaka et al. 
2000; Bianco et al. 2003; Nagata et al. 2004; Lee et al. 2005; Jiang et al. 2007). Thus, it 
is important to know whether chronic inhibition of PI3-kinase would also fail to inhibit 
the proliferation of tumor cells that do not express wild type PTEN. We found that the 
proliferation of cells expressing wild type PTEN showed reduced sensitivity to 
LY294002 during chronic exposure. In contrast, tumor cells that lacked PTEN 
expression maintained LY294002 sensitivity. In clinical use, therapeutic dosing is 
calculated to attain optimal concentrations in the blood; the optimal concentration is 
based on the effective concentration that significantly inhibited proliferation of cultured 
cells in preclinical investigations. Therefore, we treated the cells with LY294002 at 10 
M instead of gradually increasing the concentration, as is frequently done for creating 
clones that are highly resistant to particular chemicals. The results suggest that during 
treatment of human advanced cancers, tumor cells expressing wild type PTEN may 
become resistant to synthetic small molecular weight PI3-kinase inhibitors. The 
reduction in sensitivity was only about 10 - 20 fold, estimated by IC50 values. However, 
in clinical medicine, medication doses are not typically increased more than 10 times 
because of potential toxicity; generally, patients are given the highest dose that can be 
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given without adverse effects. Thus, a 10 - 20 fold reduction in sensitivity to the 
inhibitor would present a critical problem in the treatment of patients with advanced 
cancers.  
 
The reduced sensitivity to LY294002 after chronic exposure was independent of the 
phosphorylation status of Akt1, the key downstream signaling molecule of PI3-kinase, 
because Akt1 phosphorylation by external stimuli (such as serum) was maintained in the 
presence of LY294002 in DU145 (LY), PC-3 (LY), EJ-1 (LY), and UM-UC-3 (LY) cells. 
Similar results were reported in a study that showed the sensitivity of tumor cells to 
CCI-779, a potent inhibitor of mTOR, was dissociated with its ability to inhibit S6 
phosphorylation (Neshat et al. 2001). CCI-779 similarly inhibited the phosphorylation 
of S6 in both CCI-779-sensitive and -resistant cell lines. Thus, differential sensitivity to 
LY294002 is not explained by difference in biochemical detection of Akt1 activation in 
PC-3 (LY) and UM-UC-3 (LY) cells.  
 
CK2 consists of two catalytic subunits ( and ´) and a regulatory subunit (). Recent 
studies have suggested that CK2 played an important role in proliferation and survival 
of tumor cells (Ahmad et al. 2005). Downregulation of CK2 expression by siRNA or 
inhibition of its catalytic activity by the expression of dominant negative CK2 
inhibited survival and proliferation of cultured cells (Lebrin et al. 2001; Ahmad et al. 
2005); this suggested that the CK2 subunit plays major roles in cellular behaviors. 
LY294002 inhibits CK2 and PI3-kinase at similar concentrations (Stein 2001). Thus, 
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chronic exposure of cells to LY294002 may affect CK2 activity and its downstream 
targets. In addition, one function of CK2 is the phosphorylation of the C-terminal tail of 
PTEN, which stabilizes the PTEN protein (Al-Khouri et al. 2005). Thus, chronic 
inhibition of CK2 may reduce the abundance of PTEN protein. We first examined the 
expression of PTEN and CK2 in DU145 (pa), DU145 (LY), EJ-1 (pa), and EJ-1 (LY) 
cells and found that neither PTEN nor CK2 expression was altered by chronic 
exposure to LY294002 (data not shown). We then examined the effect of CK2 
downregulationon proliferation of these cells. However, downregulation did not affect 
proliferation, even in the presence of LY294002. These results suggest that the reduced 
sensitivity of proliferation to LY294002 following chronic exposure did not seem to 
depend on the CK2 activity.  
 
Another potential mechanism underlying the decreased sensitivity we observed might 
be oncogenic addiction. Serum-induced activation of ERK was lower in cells that 
lacked PTEN functionality (PC-3 and UM-UC-3 cells) than in those that possessed 
PTEN functionality (DU145 and EJ-1 cells). In addition, the stable expression of PTEN 
in PTEN-null UM-UC-3 cells reduced Akt1 phosphorylation and increased the degree 
of serum-induced ERK activation. We used siRNA for PTEN to determine the effect of 
acute downregulation of PTEN on the sensitivity of proliferation to LY294002. 
However, proliferation sensitivity to LY294002 was not affected by the acute 
downregulation of PTEN in DU145 and EJ-1 cells (data not shown). Therefore, the 
chronic loss of PTEN may cause an addiction to the PI3-kinase-dependent signaling 
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pathway, which overcomes other signaling pathways, including ERK. It has previously 
been shown that the loss of PTEN sensitized tumor cells to acute PI3-kinase inhibition 
(deGraffenried et al. 2004). Our results emphasize that a loss of PTEN would also be 
favorable for the clinical use of PI3-kinase inhibitors (chronic administration).  
 
It has been reported that the expression of PTEN strongly inhibited the growth of 
transfected cells (Furnari et al. 1998; Li and Sun 1998). The expression of wild type 
PTEN in PTEN-null tumor cells (PTEN-8 cells) did not markedly reduce the sensitivity 
of proliferation to LY294002. In EJ-1 cells, there was a 13.8-fold reduction in 
sensitivity after chronic exposure to LY294002, but in PTEN-8 cells there was only a 
4.16-fold reduction. The reason for this observation is not clear. One possibility is that 
PTEN-null cells (parental cells of PTEN-8 cells) may already have an addiction to the 
PI3-kinase/Akt pathway, and ectopic expression of wild type PTEN (such as in PTEN-8 
cells) does not alter the addiction. In this case, PTEN-8 cells may be regulated by 
different molecular machinery from PTEN-expressing cells (DU-145 and EJ-1 cells). 
Alternatively, a certain amount of PTEN expression might be required for the reduction 
in sensitivity. These issues remain to be investigated in the future.  
 
In conclusion, our study suggests that the clinical use of PI3-kinase inhibitors for the 
treatment of patients with advanced cancers may be compromised by the development 
of resistance to the inhibitors when tumor cells lose the expression of wild type PTEN. 
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Fig. 1: LY294002 treatment effects on the Akt-1 activation of human prostate 
carcinoma cells (A) Expression of PTEN protein in human prostate cancer cell lines, 
DU145 and PC-3. Proteins were visualized by immunoblotting with the indicated 
antibodies. Anti-vinculin signals indicate the relative protein content in each lane. 
Results are representative of two independent experiments. (B) Effect of LY294002 
(LY) and fetal bovine serum (FBS)-mediated phosphorylation of Akt1 in prostate cancer 
cells. Cells were either treated or left untreated with 10 M LY294002 for 30 min, and 
then were stimulated with FBS. Representative results are shown from two independent 
experiments. (C) FBS-mediated phosphorylation of Akt1 in untreated parental (pa) and 
chronically LY294002 treated (LY) prostate cancer cells. In (LY) cells, LY294002 at 10 
M was present during serum starvation and serum-treatment. Results are representative 
of two independent experiments. 
 
Fig. 2: (A) LY294002 effects on the proliferation of prostate cancer cells. Chronically 
LY294002 treated (LY) and untreated parental (pa) cells were counted after 3 days 
incubation in the presence (+) or absence (-) of LY294002 at the indicated 
concentrations. Data were expressed as means±SD of triplicate samples. Reproducible 
results were obtained from 6 experiments. Significant differences are indicated between 
the first and the last bars underneath the brackets. ＊p < 0.05. (B) LY294002 effects on 
the labeling index of prostate cancer cells. Cells in S-phase were identified by the 
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incorporation of BrdU into nuclei. Labeling index was determined as the labeled 
nuclei/total nuclei ratio and expressed as a percentage. Significant differences are 
indicated between the first and the last bars underneath the brackets. ＊p < 0.05. 
Representative results are shown from two independent experiments. 
 
Fig. 3: LY294002 treatment effects on the Akt-1 activation of human bladder cancer 
cells (A) Expression of PTEN protein in human bladder cancer cell lines EJ-1 and 
UM-UC-3. Proteins were visualized by immunoblotting with the indicated antibodies. 
Anti-vinculin signals indicate the relative protein content in each lane. Representative 
results are shown from two independent experiments. (B) Effect of LY294002 (LY) on 
FBS-mediated phosphorylation of Akt1 in bladder cancer cells. Proteins were visualized 
by immunoblotting with the indicated antibodies. Representative results are shown from 
two independent experiments. (C). FBS-mediated phosphorylation of Akt1 in untreated 
(pa) and chronically LY294002 treated (LY) bladder cancer cells. In (LY) cells, 
LY294002 at 10 M was present during serum starvation and serum-treatment. 
Representative results are shown from two independent experiments. 
 
Fig. 4: Effect of CK2 siRNA on proliferation of human prostate and bladder cancer 
cells. (A) CK2ablation in chronically LY294002 treated (LY) and untreated parental 
(pa) prostate cancer (DU145) and bladder cancer (EJ-1) cells treated with either control 
or CK2 siRNA for 3 days. Proteins were visualized by immunoblotting with the 
indicated antibodies. Anti-vinculin signals indicate the relative protein content in each 
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lane. Representative results are shown from two independent experiments. (B) Effect of 
CK2 siRNA on the proliferation of DU145 and EJ-1 cells. Chronically LY294002 
treated (LY) and untreated parental (pa) cells were counted after 3-day incubations in 
the presence (+) or absence (-) of LY294002 and either control or CK2 siRNA (50 
nM). Data were expressed as means±SD of triplicate samples. Representative results 
are shown from two independent experiments. Significant differences are indicated 
between the bars under the brackets.＊p < 0.05. 
 
Fig. 5: Effect of PD98059 on MAPK/ERK activation and proliferation of prostate and 
bladder cancer cells. (A) Effect of PD98059 on fetal bovine serum FBS-mediated 
phosphorylation of ERK (phosphoMAPK) in prostate (DU145 and PC-3) and bladder 
(EJ-1 and UM-UC-3) cancer cells. Cells were incubated at the indicated concentration 
of PD98059 for 3 days. Proteins were visualized by immunoblotting with the indicated 
antibodies. Representative results are shown from two independent experiments. (B) 
Effect of PD98059 on proliferation of prostate and bladder cancer cells. After 
incubation in the indicated concentration of PD98059 for 3 days, cell number was 
counted. Data were expressed as means±SD for triplicate samples. Representative 
results are shown from two independent experiments. Significant differences are 
indicated between the bars under the brackets. ＊p < 0.05. 
 
Fig. 6: Effects of PTEN expression on ERK and Akt-1 activation and proliferation of 
human bladder cancer cells. (A) Expression of wild type PTEN (PTEN-8) in human 
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bladder cancer cell line, UM-UC-3. EJ-1 cells are shown to indicate endogenous 
expression levels of PTEN. Mock indicates a transfection of empty vector in UM-UC-3 
cells, and shows the absence of endogenous PTEN expression. Proteins were visualized 
by immunoblotting with the indicated antibodies. Anti-vinculin signals indicate the 
relative protein content in each lane. Representative results are shown from two 
independent experiments. (B) FBS-induced activation of ERK (phosphoMAPK) in 
Mock and PTEN-8 cells. Proteins were visualized by immunoblotting with the indicated 
antibodies. Anti-vinculin signals indicate the relative protein content in each lane. 
Representative results are shown from two independent experiments. (C) FBS-induced 
phosphorylation of Akt1 in Mock and PTEN-8 cells. Proteins were visualized by 
immunoblotting with the indicated antibodies. Representative results are shown from 
two independent experiments. (D) Effects of PD98059 and LY294002 on the 
proliferation of Mock and PTEN-8 cells. Cells were counted after 3-day incubations in 
the presence (+) or absence (-) of LY294002 and/or PD98059 at the concentrations 
indicated. Data were expressed as means±SD for triplicate samples. Representative 
results are shown from two independent experiments. Significant differences are 
indicated between the bars under the brackets. ＊p < 0.05. 
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 Table 1. IC50 values for LY294002 treatment in parental and chronically treated 
human prostate and bladder cancer cells. 
______________________________________________________________________ 
      cells                           IC50 values (M)             
  DU145 (pa) cells                       1.36 ± 0.88 
  DU145 (LY) cells                      29.13 ± 15.2   
 
  PC-3 (pa) cells                         3.23 ± 1.58 
  PC-3 (LY) cells                        3.70 ± 2.44 
 
  EJ-1 (pa) cells                         1.43 ± 0.63 
  EJ-1 (LY) cells                        19.73 ± 8.34 
 
  UM-UC-3 (pa) cells                    2.63 ± 1.91 
  UM-UC-3 (LY) cells                   2.90 ± 2.22 
______________________________________________________________________ 
(LY), cultured in the presence of LY294002; (pa) cultured in the absence of LY294002 
Values are expressed as means ± SD from 3 to 6 independent examinations. 
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Table 2. IC50 values of parental, Mock-transfected, and PTEN-expressing cells 
(PTEN-8 cells) chronically treated with or without LY294002. 
______________________________________________________________________ 
      cells                                        IC50 values (M)   
 
  Untransfected UM-UC-3 (pa) cells                      6.03 ± 2.64 
  Untransfected UM-UC-3 (LY) cells                     7.09 ± 4.14 
 
  Mock-transfected UM-UC-3 (pa) cells                   4.63 ± 1.90 
  Mock-transfected UM-UC-3 (LY) cells                  5.74 ± 3.42 
 
  PTEN-8 (pa) cells                                   4.33 ± 2.65 
  PTEN-8 (LY) cells                                 18.00 ± 5.90 
______________________________________________________________________ 
(LY) cultured in the presence of LY294002; (pa) cultured in the absence of LY294002. 
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